- FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab) Merck.com
- FDA OKs New Keytruda Shot for Cancer The New York Times
- FDA Approves Subcutaneous Pembrolizumab for Solid Tumors OncLive
- US FDA approves Merck’s injectable version of blockbuster cancer therapy Keytruda Reuters
- Merck wins approval of subcutaneous Keytruda, in bid to extend life of world’s top-selling drug Endpoints News
Source link
